Published in Clinical Oncology Week, February 21st, 2011
"Our hypothesis was that MET and GBM tumors differ in morphology. Shape analysis was proposed as an indicator for discriminating these 2 types of brain pathologies," wrote L. Blanchet and colleagues, Radboud University, Institute for Molecules and Materials.
The researchers concluded: "The purpose...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.